| 1 |
Arjun S,Ponni P.Recent developments in diagnosis of pancreatic cancer.BMJ,2004,329:668-673.
|
| 2 |
Ozkan H,Kaya M, Cengiz A. Comparison of tumor marker CA242 with CA19-9 and carcinoembryonic antigen(CEA)in pancreatic cancer. Hepatogastroenterology,2003,50(53):1669-1674.
|
| 3 |
Koopmann J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as marker of pancreatic and other periampullary cancers. Clin Cancer Res,2004,10(7):2386-2392.
|
| 4 |
Koopmann J,Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.Clin Cancer Res,2006,12(2):442-446.
|
| 5 |
Novotny I,Ditě P, Dastych M, et al. Tumor marker M2-pyruvate-kinase in differential diagnosis of chronic pancreatitis and pancreatic cancer. Hepatogastroenterology.2008,55(85):1475-1477.
|
| 6 |
Cerwenka H,Aigner R,Bacher H,et al.TUM2-PK(pyruvate kinase type tumor M2),CA19-9 and CEA in patients with benign,malignant and metastasizing pancreatic lesions.Anticancer Res,1999,19(1B):849-851.
|
| 7 |
Ventrucci M, Cipolla A, Racchini C, et al. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci, 2004, 49(7-8):1149-1155.
|
| 8 |
Kolb A,Kleeff J,Guweidhi A,et al.Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions.Cancer Biol Ther,2005,4(7):740-746.
|
| 9 |
Iacobuzio-Donahue CA,Maitra A,Shen-Ong GL,et al.Discovery of novel tumor markers of pancreatic cancer using global gene expression technology.Am J Pathol,2002,160(4):1239-1249.
|
| 10 |
Koopmann J, Fedarko NS, Jain A, et al. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomar kers Prev,2004,13(3):487-491.
|
| 11 |
Koji Y,Munechika E,Manabu N,et al.Novel serum tumor marker,RCAS1 in pancreatic diseases.World J Gastroenterol,2005,11:51 99-5202.
|
| 12 |
Giaginis C,Davides D,Zarros A,et al.Clinical significance of tumor-associated antigen RCAS1 expression in human pancreatic ductal adenocarcinoma.Dig Dis Sci,2008,53(6):1728-1734.
|
| 13 |
Tetsuro A，Hideki O，Kenichi N，et al.Expression and diagnostic evaluation of the human tumor associated antigen RCAS1 in pancreatic cancer.Pancreas,2003，26:49-55.
|
| 14 |
Kobayashi N, Inamori M, Fujita K, et al. characterization of K-ras gene mutations in association with mucinous hypersecretion in intraductal papillary-mucinous neoplasms,2008,15(2):169-177.
|
| 15 |
D britz J,Preston R,Ha..nfler J,et al.Follow-up study of K-ras mutations in the plasma of patients with pancreatic cancer:correlation with clinical features and carbohydrate antigen 19-9.Pancreas,2009,16.
|
| 16 |
Peng B,Fleming JB,Breslin T,et al.Suppression of tumorigenesis and induction of p15(ink4b)by Smad4/DPC4 in human pancreatic cancer cells.Clin Cancer Res, 2002,8(11):3628-3638.
|
| 17 |
Yoo CB, Valente R, Congiatu C, et al. Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine.J Med Chem,2008,51(23):7593-7601.
|
| 18 |
Lee MA,Park GS,Lee HJ,et al.Survivin expression and its clinical significance in pancreatic cancer.BMC Cancer,2005,5:127.
|
| 19 |
Sun HC, Qiu ZJ, Liu J, et al. Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis.Int J Oncl,2007,30(6):1359-1367.
|
| 20 |
Satoh K,Kaneko K,Hirota M,et al.Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors.Cancer,2001,92(2):271-278.
|
| 21 |
Crnogorac-Jurcevic T,Missiaglia E,Blaveri E,et al.Molecular alterations in pancreatic carcinoma:expression profiling shows that dysregulated expression of S100 genes is highly prevalent.J Pathol,200 3,201(1):63-74.
|
| 22 |
Ligato S,Zhao H,Mandich D,et al.KOC(K homology domain containing protein overexpressed in cancer) and S100A4-protein immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology for diagnosing pancreaticobiliary malignancies,2008,36(8):561-567.
|
| 23 |
Inami K, Kajino K, Abe M, et al. Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. Oncol Rep,2008,20(6):1375-1380.
|
| 24 |
Grubbs EG,Abdel-Wahab Z, Tyler DS, et al. Utilizing quantitative polymerase chain reaction to evaluate prostate stem cell antigen as a tumor marker in pancreatic cancer.Ann Surg Oncol,2006,13(12):1645-1654.
|
| 25 |
Tanaka M,Komatsu N,Terakawa N,et al.Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients.Oncol Rep,2007,18(1):161-166.
|
| 26 |
McCarthy DM,Maitra A,Argani P,et al.Novel markers of pancreatic adenocarcinoma in fine-needle aspiration:mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases.Appl Immunohistochem Mol Morphol,2003,11(3):238-243.
|